Overview

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland, Baltimore
Treatments:
3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
Gemcitabine